ISRL - ETF AI Analysis
Top Page
Defiance KSM Israel 120 ETF (ISRL)
ISRL, the Defiance KSM Israel 120 ETF, has a solid overall rating driven mainly by its large positions in strong Israeli financial names like Bank Leumi, Mizrahi Tefahot, Poalim, Phoenix, and Harel, which show healthy financial performance, generally bullish price trends, and reasonable valuations. However, holdings such as Elbit Systems and Teva introduce some drag on the fund’s rating due to bearish or mixed technical signals, valuation concerns, and leverage or profitability issues. The main risk factor is the ETF’s heavy concentration in Israel’s financial sector, which can increase sensitivity to local economic and regulatory conditions.
ISRL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.17M
- Region
- Middle East & Africa
- Expense Ratio
- 0.59%
- Beta
- -0.89
- Issuer
- Defiance
- Inception Date
- Aug 31, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- Israeli 120 iNDEX - ILS - Benchmark TR Net
ISRL Summary
ISRL is an exchange-traded fund that follows the Israeli 120 Index, giving you broad exposure to about 120 of the largest companies listed in Israel. It includes major banks like Poalim and Leumi, as well as global drugmaker Teva and defense company Elbit Systems, across sectors such as finance, healthcare, and technology. An investor might choose ISRL to add international diversification and focused exposure to Israel’s economy within a larger portfolio. A key risk is that, as a single-country fund, its value can rise or fall sharply with economic or political events in Israel.
How much will it cost me?
This ETF has an expense ratio of 0.59%, which means you’ll pay about $5.90 per year for every $1,000 you invest. That’s higher than the average cost of broad, passively managed index ETFs, mainly because it offers more specialized, single-country exposure to Israel’s stock market.
What would affect this ETF?
This ETF is heavily tied to Israel’s economy and financial sector, so stronger local growth, stable regional conditions, and healthy bank profits could support future performance, while political tensions or economic slowdowns in Israel could hurt it. Global interest rate cuts and positive trends in technology and healthcare could benefit top holdings like banks, defense, and pharma companies, but higher rates, regulatory changes, or sector-specific challenges for these firms could weigh on returns.
ISRL Top 10 Holdings
ISRL is essentially a bet on Israel’s financial backbone, with big banks like Poalim, Leumi, and Mizrahi Tefahot setting the tone. These lenders have been steady to rising over the past few months, helping support the fund even when short-term moves look choppy. On the growth side, Teva and Phoenix have been climbing, adding some extra fuel, while Tower’s recent slide has acted as a bit of a speed bump. Overall, this is a domestically focused, Israel-only play with a tilt toward financials and a dash of healthcare and tech.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 IL:ESLT | Elbit Systems | 4.68% | $54.66K | ILS 114.84B | 57.88% | 73Outperform |
 IL:POLI | Poalim | 4.45% | $51.95K | ILS 94.98B | 14.29% | 79Outperform |
 IL:LUMI | Leumi | 4.46% | $52.04K | ILS 105.71B | 13.65% | 80Outperform |
 IL:MZTF | Mizrahi Tefahot | 4.24% | $49.58K | ILS 57.46B | 8.86% | 80Outperform |
 IL:TEVA | Teva | 3.85% | $44.92K | ILS 149.16B | 94.35% | 61Neutral |
 IL:TSEM | Tower | 3.77% | $44.00K | ILS 59.43B | 105.94% | ―― |
 IL:AZRG | Azrieli Group | 3.30% | $38.53K | ILS 43.63B | 3.47% | 68Neutral |
 IL:PHOE | Phoenix | 3.18% | $37.11K | ILS 42.92B | 39.90% | 79Outperform |
 IL:DSCT | Discount | 2.96% | $34.53K | ILS 40.20B | 5.58% | 75Outperform |
 IL:HARL | Harel | 2.73% | $31.93K | ILS 37.11B | 64.93% | 76Outperform |
ISRL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ISRL, the sentiment is Negative. The current price of 22.61 is below the 20-day moving average (MA) of 23.69, compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 4.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISRL.
ISRL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| ISRL | $22.61 | $25.00(10.57% Upside) | $1.17M | 0.59% | 58Neutral |
 ISRA | $63.97 | ― | $156.13M | 0.59% | 68Neutral |
 RCGE | $30.46 | $33.90(11.29% Upside) | $98.52M | 0.95% | 59Neutral |
 PRMR | $28.30 | $34.26(21.05% Upside) | $93.63M | 1.00% | 73Outperform |
 OAKI | $26.59 | $31.66(19.06% Upside) | $93.33M | 0.65% | 58Neutral |
 BCIL | $28.11 | $35.36(25.80% Upside) | $90.30M | 0.80% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ISRL | Defiance KSM Israel 120 ETF | 22.61 | -2.06 | -8.34% | |
| ISRA | VanEck Israel ETF | 63.97 | 8.93 | 16.23% | |
| RCGE | RockCreek Global Equality ETF | 30.46 | 3.29 | 12.13% | |
| PRMR | PeakShares RMR Prime Equity ETF | 28.30 | 3.32 | 13.31% | |
| OAKI | Oakmark International Large Cap ETF | 26.59 | 1.01 | 3.94% | |
| BCIL | Bancreek International Large Cap ETF | 28.11 | 0.09 | 0.33% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.